Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 31, 2026

The Sell-Off In Gold May Be Last Stop Before $10,000 – 5 Stocks and an ETF To Buy Now

View original at finance.yahoo.com
The Sell-Off In Gold May Be Last Stop Before $10,000 – 5 Stocks and an ETF To Buy Now The case for gold and gold miners is compelling for two reasons…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Diversification away from U.S. dollar reserve holdings, while still moderate, has accelerated in recent years

    80% confidence
  • Agnico Eagle Mines rated Buy

    80% confidence
  • In the long term, analysts expect gold to trade between $10,000 and $16,150 over the next 10 years

    80% confidence
  • Newmont Corporation rated Outperform

    80% confidence
  • Gold will reach $10,000 per ounce by 2028

    80% confidence
  • Gold will reach $5,000 per ounce by 2026

    80% confidence
  • Gold could reach $10,000 per ounce before the end of the decade if it continues on its current path

    80% confidence
  • Wheaton Precious Metals rated Buy

    80% confidence
  • Franco-Nevada rated Buy

    80% confidence
  • Barrick Gold rated Buy

    80% confidence
  • The demand for Gold will remain consistent over the next 5 to 10 years, according to some opinions from Wall Street

    80% confidence
  • Silver is not considered as much of an asset hedge or a store of value like gold

    80% confidence
  • The most powerful structural force is the global shift in reserve holdings, with central banks continuing to increase the percentage of gold in their international reserves

    80% confidence

Data points we hold from this source

UBS Group AG · target price270 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com